ResMed Forecasts FY 2027 Revenue of $5.75B-$5.85B and EPS of $12-$12.25, Accelerates Shareholder Returns

ResMed expects fiscal year 2027 revenue to be between $5.75 billion and $5.85 billion, with non-GAAP EPS of $12 to $12.25, alongside accelerating over $1.85 billion in shareholder returns.